Increasing number of surgical procedures worldwide, along with growing geriatric population prone to various disorders, is anticipated to drive the market. In addition, growing number of conditions such as sun radiation sores, pressure sores, foot ulcers caused by diabetes, and disorders caused by bad blood circulation are expected to fuel the market in the future. Growing prevalence of diabetes is also expected to fuel the market over the next few years. According to the International Diabetes Federation, approximately 425 million adults in the age group 20-79 years suffered from diabetes in 2017 and this number is expected to cross 629 million by the end of 2045. Diabetic patients are expected to develop slow healing wounds, which can cause wounds to rot easily and cause various complications ranging from infection near the tissue or bone to life-threatening cases. For instance, foot ulcers due to diabetes are expected to affect 1 in 4 patients with diabetes, which, on progression, could lead to foot amputation. As per an article in the American Journal of Managed Care (AJMC), approximately 230 amputations due to diabetes are reported in the U.S.

NeuEsse Inc. plans to establish our pipeline of technologies to help alleviate pain, suffering and costs associated with the acute and chronic wound explosion anticipated globally. OmegaSkin™ and QuikSkin liquid skin spray will be available at a lower cost and promises of greater efficacy and patient satisfaction as full thickness wound have proven to heal with minimal to no scarring. Healing with OmegaSkin also promises functioning hair follicles and sweat glands instead of thick slick scars left by many occlusive dressings. All-natural plant-based human skin substitute offers advantages to many over pig, cow and cadaver products in today’s market.